Coronavirus Outbreak

Publishing Incentives Keep Scientists From Covid Collaboration

Sept. 16, 2020, 6:52 PM

U.S. pandemic efforts are hampered by an academic structure that rewards scientists more for publishing small studies than cooperating on large, collaborative research, the FDA’s biologics chief said.

Peter Marks, director of the Food and Drug Administration Center for Biologics Evaluation and Research, said he’s seen companies shake up their corporate structure and collaborate in unique ways they weren’t doing before the Covid-19 pandemic. But in academia, it “seems like it’s almost business as usual and that’s been a little bit shocking to me,” he said during a virtual event on public policy in regenerative medicine and cell therapies.


To read the full article log in.